#USA #TransMedics #TMDX #organ transplant #Andover, Massachusetts

TransMedics Financial Performance Update

TransMedics Group, Inc. (NASDAQ: TMDX), renowned for pioneering organ transplant therapies, has recently shared significant updates regarding its financial results for the fourth quarter of 2025. The company reported the release of a $103.3 million U.S. tax valuation allowance, which has significantly influenced its net income tax benefit for the quarter.

The decision to release this valuation allowance stems from TransMedics' reassessment of its future income prospects, leading them to believe that the utilization of deferred tax assets has become a likely scenario. This strategic move has allowed the company to record an impressive net income tax benefit amounting to $83.8 million for the quarter.

The implications of this release are notable. TransMedics disclosed that its annual effective tax rate for 2025 stood at an impressive (77.0)%. Without the effect of the valuation allowance release, the effective rate would have been approximately 19.1%, marking a substantial discrepancy of 96.1 percentage points. This difference highlights the substantial impact the valuation allowance has had on TransMedics' tax obligations.

In concrete terms, when applying the standard effective tax rate of 19.1% to the fourth-quarter income before tax, which totaled $21.6 million, the resultant adjusted tax expense would have been around $4.1 million. Consequently, the net income recorded for the fourth quarter reached $105.4 million, translating to a net income per diluted share of $2.62. When factoring in the annual effective tax rate, the adjusted net income amounts to approximately $17.5 million, resulting in a revised net income per diluted share of $0.47.

Looking ahead, TransMedics indicates that it expects future quarterly income tax provisions to align more closely with statutory corporate income tax rates in the U.S. This forecast comes from a commitment to stabilize operational costs and optimize tax efficiencies as the company moves forward in its mission to enhance organ transplant procedures.

About TransMedics

Based in Andover, Massachusetts, TransMedics Group is at the forefront of transforming organ transplant therapies for patients experiencing end-stage heart, lung, and liver failure. The company's innovations include the development of portable extracorporeal warm perfusion technology, which aims to improve organ viability and increase the availability of donor organs.

TransMedics strives to tackle the pressing need for improved organ transplantation solutions, thereby enhancing patient outcomes. Through its dedication to research and development, the company positions itself as a leading name in medical technology and organ transplant innovation.

Non-GAAP Financial Measures

The financial statements released by TransMedics include non-GAAP measures, which offer a perspective on the company's operational performance. These metrics are not standardized by GAAP and should not be viewed as substitutes for the required GAAP measures. TransMedics believes that these indicators provide insightful data for evaluating its ongoing operations.

Forward-Looking Statements

The content of this release contains forward-looking statements, which encompass expectations related to future outcomes. Such statements, while optimistic, are subject to risks and uncertainties that may cause actual results to differ. Factors affecting these predictions include financial performance fluctuating from quarter to quarter, evolving healthcare policies, and the company’s ability to manage operational challenges effectively.

As TransMedics continues to grow and expand its product offerings, the upcoming quarters are anticipated to deliver promising advancements in the realm of organ transplantation, guided by innovative solutions and strategic financial management.